Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

No, You Do Not Hear the Fat Lady Warming Up

Those who never predicted a financial collapse in the first place are now edging closer to the swamp to dip their toes into the water. Now they are suggesting, perhaps we could have a recession. " Forget that. You cannot have every supply chain in the world chopped in ...
Streetwise Reports | March 30, 2020 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. In a Feb. 19 research note, analyst Yasmeen Rahimi reported that CymaBay Therapeutics Inc. (CBAY:NASDAQ) is having a strong Q1/19 with respect to cont...
Streetwise Reports | February 26, 2019 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Excess Money Supply Has Been Like Miracle-Gro for Gold Prices

The $2.2 trillion coronavirus relief package that President Donald Trump signed into law on March 27 is just the beginning. The Treasury Department is now seeking some $250 billion more to replenish small business loans, and there’s hope that the president...
Frank Holmes | April 9, 2020 |

A massive bull market is building for gold

Imagine, if you will, there was no coronavirus. No haz-mat suits, medical masks & gloves, no make-shift morgues. No terminally ill patients hooked up to ventilators, no horrible deaths without love ones close, no lockdowns, no social distancing, no deserted streets, no bailo...
Richard (Rick) Mills | April 17, 2020 |

3 Tips for Picking Junior Gold Stocks

As the correction in gold stocks continues and as it’s likely to endure for the time being, we take a step back and share some tips for selecting individual junior gold companies. The current correction may provide the last chance to buy before the bull mar...
Jordan Roy-Byrne, CMT | October 9, 2019 |

Large US Market Now Open to Livestock Feed Antibiotic Replacement

Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. Antibiotic resistance is a major health threat worldwide and many countries have banned or are banning the use of antibiotics as growth promoters in livestock. The European...
Streetwise Reports | March 12, 2019 |

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |
1 2 3 4 5 6 7 8 9 10 ...